These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 16505438)

  • 1. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
    Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
    J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography/ computed tomography for N-and M-staging of malignant melanoma].
    Gu H; Xu W; Song X; Dai D; Zhu L; Wang J
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(17):1309-12. PubMed ID: 25142850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
    Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
    Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
    Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
    J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
    Antoch G; Vogt FM; Freudenberg LS; Nazaradeh F; Goehde SC; Barkhausen J; Dahmen G; Bockisch A; Debatin JF; Ruehm SG
    JAMA; 2003 Dec; 290(24):3199-206. PubMed ID: 14693872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
    Falk MS; Truitt AK; Coakley FV; Kashani-Sabet M; Hawkins RA; Franc B
    Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma.
    Veit-Haibach P; Vogt FM; Jablonka R; Kuehl H; Bockisch A; Beyer T; Dahmen G; Rosenbaum S; Antoch G
    Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):910-8. PubMed ID: 19156409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study.
    Jouvet JC; Thomas L; Thomson V; Yanes M; Journe C; Morelec I; Bracoud L; Durupt F; Giammarile F; Berthezene Y
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):176-85. PubMed ID: 23331931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
    Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
    Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
    Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.